Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza a viruses isolated from wild birds

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Orozovic, Goran ^a,b   Orozovic, Kanita ^a   Lennerstrand, Johan ^b   Olsen, Björn ^b  

^a LINNAEUS UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; OSELTAMIVIR; SIALIDASE; VIRUS RNA; ZANAMIVIR; ANTIVIRUS AGENT;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; AVIAN INFLUENZA VIRUS; BIOINFORMATICS; BIRD; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE DATABASE; SWEDEN; SWINE; VIRUS ISOLATION; WILD SPECIES; ANIMAL; AVIAN INFLUENZA; BIOLOGY; DNA SEQUENCE; DRUG EFFECT; DUCK; GENETICS; INFLUENZA VIRUS A; ISOLATION AND PURIFICATION; METHODOLOGY; MISSENSE MUTATION; NUCLEIC ACID DATABASE; VIROLOGY;

ANAS PLATYRHYNCHOS; AVES; INFLUENZA A VIRUS; SUIDAE;

ANIMALS; ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; DATABASES, NUCLEIC ACID; DRUG RESISTANCE, VIRAL; DUCKS; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; MUTATION, MISSENSE; OSELTAMIVIR; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SWINE; ZANAMIVIR;

EID: 79251537801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016028     Document Type: Article

References (62)

1. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: Past and present. Annual Review of Medicine 51: 407-421.
2. Ferguson NM, Cummings DAT, Fraser C (2006) Strategies for mitigating an influenza pandemic. Nature 442: 448-453.
3. Taubenberger JK, Kash JC (2010) Influenza Virus Evolution, Host Adaptation, and Pandemic Formation. Cell Host & Microbe 7: 440-451.
4. Deshpande JD, Phalke DB, Phalke VD (2009) ''Swine Flu'': The return of pandemic. Pravara Medical Review 4: 4-7.
5. Malik Peiris JS, Poon LLM, Guan Y (2009) Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. Journal of Clinical Virology 45: 169-173.
6. Steinhauer DA, Skehel JJ (2002) Genetics of influenza viruses. Annual Review of Genetics 36: 305-332.
7. Monto AS (2006) Vaccines and Antiviral Drugs in Pandemic Preparedness. Emerging Infectious Diseases 12: 55-61.
8. Oshitani H (2006) Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic. Journal of Infection and Chemotherapy 12: 167-171.
9. Germann TC, Kadau K, Longini IM, Macken CA (2006) Mitigation Strategies for Pandemic Influenza in the United States. Proceedings of the National Academy of Sciences of the United States of America 103: 5935-5940.
10. Baigent SJ, Bethell RC, McCauley JW (1999) Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro. Virology 263: 323-338.
11. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG (2001) Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrobial Agents and Chemotherapy 45: 2723-2732.
12. Gubareva LV (2004) Characterization of influenza A and B viruses recovered from immunocompromised patients treated with antivirals. In: Kawaoka Y, ed. Options for the Control of Influenza V. pp 126-129.
13. Gubareva LV (2004) Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Research 103: 199-203.
14. Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrobial Agents and Chemotherapy 45: 3403-3408.
15. McKimm-Breschkin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Research 47: 1-17.
16. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et al. (2009) Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. Jama-Journal of the American Medical Association 301: 1034-1041.
17. Harvala H, Gunson R, Simmonds P, Hardie A, Bennett S, et al. (2010) The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. Eurosurveillance 15: 2-4.
18. Weinstock DM, Zuccotti G (2009) The Evolution of Influenza Resistance and Treatment. Jama-Journal of the American Medical Association 301: 1066-1069.
19. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, et al. (2010) Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. Journal of General Virology 91: 949-959.
20. Hill AW, Guralnick RP, Wilson MJC, Habib F, Janies D (2009) Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza. Infection Genetics and Evolution 9: 169-178.
21. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, et al. (2007) Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. Journal of Virology 81: 12418-12426.
22. Govorkova EA, Webster RG (2010) Combination Chemotherapy for Influenza. Viruses 2: 1510-1529.
23. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Research 70: 121-131.
24. Poland GA, Jacobson RM, Ovsyannikova IG (2009) Influenza Virus Resistance to Antiviral Agents: A Plea for Rational Use. Clinical Infectious Diseases 48: 1254-1256.
25. Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenstrom J, et al. (2007) Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus. Plos One 2.
26. Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B (2009) Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 75: 28-33.
27. Singer AC, Nunn MA, Gould EA, Johnson AC (2007) Potential risks associated with the proposed widespread use of Tamiflu. Environmental Health Perspectives 115: 102-106.
28. Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, et al. (2009) Detection of the Antiviral Drug Oseltamivir in Aquatic Environments. Plos One 4.
29. Ghosh GC, Nakada N, Yamashita N (2010) Oseltamivir Carboxylate, the Active Metabolite of Oseltamivir Phosphate (Tamiflu), Detected in Sewage Discharge and River Water in Japan. Environmental Health Perspectives 118: 103-108.
30. Wallensten A, Munster VJ, Latorre-Margalef N (2007) Surveillance of Influenza A Virus in Migratory Waterfowl in Northern Europe. Emerging Infectious Diseases 13: 404-412.
31. Orozovic G, Latorre-Margalef N, Wahlgren J, Muradrasoli S, Olsen B (2010) Degenerate primers for PCR amplification and sequencing of the avian influenza A neuraminidase gene. Journal of Virological Methods 170: 95-99.
32. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Archives of Virology 146: 2275-2289.
33. Bloom JD, Gong LI, Baltimore D (2010) Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance. Science 328: 1272-1275.
34. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, et al. (2007) Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 73: 228-231.
35. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA (2010) Effect of Neuraminidase Inhibitor-Resistant Mutations on Pathogenicity of Clade 2.2 A/ Turkey/15/06 (H5N1) Influenza Virus in Ferrets. Plos Pathogens 6.
36. Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. Journal of Clinical Virology 41: 13-19.
37. Ho HT, Hurt AC, Mosse J, Barr I (2007) Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues. Antiviral Research 76: 263-266.
38. Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, et al. (2010) Host cell selection of influenza neuraminidase variants: Implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Research 85: 381-388.
39. Richard M, Deleage C, Barthelemy M, Lin YP, Hay A, et al. (2008) Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. Journal of Clinical Virology 41: 20-24.
40. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, et al. (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. Journal of Virology 80: 8787-8795.
41. Hurt AC, Holien JK, Barr IG (2009) In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses. Antimicrobial Agents and Chemotherapy 53: 4433-4440.
42. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG (2009) Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation. Journal of Virology 83: 10366-10373.
43. Ferraris O, Kessler N, Lina B (2005) Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Research 68: 43-48.
44. Matrosovich M, Klenk HD (2003) Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Reviews in Medical Virology 13: 85-97.
45. Munster VJ, Baas C, Lexmond P, Waldenstrom J, Wallensten A, et al. (2007) Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds. Plos Pathogens 3: 630-638.
46. Munster VJ, Wallensten A, Baas C, Rimmelzwaan GF, Schutten M, et al. (2005) Mallards and highly pathogenic avian influenza ancestral viruses, northern Europe. Emerging Infectious Diseases 11: 1545-1551.
47. Cong YL, Pu J, Liu OF, Wang S, Zhang GZ, et al. (2007) Antigenic and genetic characterization of H9N2 swine influenza viruses in China. Journal of General Virology 88: 2035-2041.
48. Yu H, Hua RH, Wei TC, Zhou YJ, Tian ZJ, et al. (2008) Isolation and genetic characterization of avian origin H9N2 influenza viruses from pigs in China. Veterinary Microbiology 131: 82-92.
49. Vincent AL, Ma WJ, Lager KM, Janke BH, Richt JA (2008) Swine Influenza Viruses: A North American Perspective. Advances in Virus Research 72: 127-154.
50. Dugan VG, Chen R, Spiro DJ, Sengamalay N, Zaborsky J, et al. (2008) The evolutionary genetics and emergence of avian influenza viruses in wild birds. Plos Pathogens 4.
51. Li J, Dohna Hz, Anchell NL (2010) Adaptation and transmission of a duckorigin avian influenza virus in poultry species. Virus Research 147: 40-47.
52. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, et al. (2002) Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Research 54: 79-88.
53. Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, et al. (2008) Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrobial Agents and Chemotherapy 52: 3687-3693.
54. Morrison D, Roy S, Rayner C, Amer A, Howard D, et al. (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. Plos Clinical Trials 2.
55. Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, et al. (2008) Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrobial Agents and Chemotherapy 52: 3484-3491.
56. Gubareva LV, Robinson MJ, Bethell RC, Webster RG (1997) Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. Journal of Virology 71: 3385-3390.
57. Hurt AC, Barr IG, Hartel G, Hampson AW (2004) Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Research 62: 37-45.
58. Abed Y, Nehme B, Baz M, Boivin G (2008) Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Research 77: 163-166.
59. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus A, et al. (2006) Global patterns of influenza A virus in wild birds. Science 312: 384-388.
60. Lauring AS, Andino R (2010) Quasispecies Theory and the Behavior of RNA Viruses. Plos Pathogens 6.
61. Aoki FY, Boivin G, Roberts N (2007) Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy 12: 603-616.
62. Musiychuk K, Stephenson N, Bi H, Farrance CE, Orozovic G, et al. (2007) A launch vector for the production of vaccine antigens in plants. Influenza and Other Respiratory Viruses 1: 19-25.